Clinical trial
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176)…
NCT05412004 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT05412004 |
|---|---|
| Title | Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea |
| Official title | A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial |
| Acronym | SURMOUNT-OSA |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Obstructive Sleep Apnea, Obesity |
| Intervention type | Drug |
| Interventions | Tirzepatide, Placebo |
| Enrollment | 469 |
| Start date | Jun 21, 2022 |
| Primary completion | Mar 12, 2024 |
| Completion | Mar 29, 2024 |
| First posted | Jun 9, 2022 |
| Last update posted | Apr 30, 2025 |
| Countries | Australia, Brazil, China, Czechia, Germany, Japan, Mexico, Puerto Rico, Taiwan, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: